How do you plan to integrate nerandomilast into the treatment algorithm for patients with ILD?  

That’s a great question and one we’re all still actively defining in real time as this new agent enters practice.First, I always start with the basics—diagnosis and disease behavior. Before starting any antifibrotic, I make sure the ILD diagnosis is solid through multidisciplinary ...

Dr. @Santibanez has eloquently discussed the expected use of nerandomilast above. The decision that I foresee myself struggling with is whether to use nerandomilast as an add-on agent or a replacement for those patients already on anti-fibrotic therapy but continues to decline. While it showed effi...

Given that its efficacy is similar to what we already have, it's probably the drug I would start someone on as a new start, just given the side effect profile and lack of drug monitoring. If patients are tolerating esb or ofev at the max dose, I wouldn't see any reason to change them over to nerando...